PMID- 36318608
OWN - NLM
STAT- MEDLINE
DCOM- 20230323
LR  - 20230327
IS  - 1537-6591 (Electronic)
IS  - 1058-4838 (Print)
IS  - 1058-4838 (Linking)
VI  - 76
IP  - 6
DP  - 2023 Mar 21
TI  - New Perspectives for Prosthetic Valve Endocarditis: Impact of Molecular Imaging 
      by FISHseq Diagnostics.
PG  - 1050-1058
LID - 10.1093/cid/ciac860 [doi]
AB  - BACKGROUND: The microbial etiology of prosthetic valve infective endocarditis 
      (PVE) can be difficult to identify. Our aim was to investigate the benefit of 
      molecular imaging technique fluorescence in situ hybridization (FISH) combined 
      with 16S rRNA-gene polymerase chain reaction (PCR) and sequencing (FISHseq) for 
      the analysis of infected prosthetic heart valves. METHODS: We retrospectively 
      evaluated the diagnostic outcome of 113 prosthetic valves from 105 patients with 
      suspected PVE, treated in 2003-2013 in the Department of Cardiac Surgery, Charite 
      University Medicine Berlin. Each prosthetic valve underwent cultural diagnostics 
      and was routinely examined by FISH combined with 16S rRNA gene PCR and 
      sequencing. We compared classical microbiological culture outcomes (blood and 
      valve cultures) with FISHseq results and evaluated the diagnostic impact of the 
      molecular imaging technique. RESULTS: Conventional microbiological diagnostic 
      alone turned out to be insufficient, as 67% of preoperative blood cultures were 
      noninformative (negative, inconclusive, or not obtained) and 67% of valve 
      cultures remained negative. FISHseq improved the conventional cultural diagnostic 
      methods in PVE in 30% of the cases and increased diagnostic accuracy. Of the 
      valve culture-negative PVE cases, FISHseq succeeded in identifying the causative 
      pathogen in 35%. CONCLUSIONS: FISHseq improves PVE diagnostics, complementing 
      conventional cultural methods. In addition to species identification, FISH 
      provides information about the severity of PVE and state of the pathogens (eg, 
      stage of biofilm formation, activity, and localization on and within the 
      prosthetic material). As a molecular imaging technique, FISHseq enables the 
      unambiguous discrimination of skin flora as contaminant or infectious agent.
CI  - (c) The Author(s) 2022. Published by Oxford University Press on behalf of 
      Infectious Diseases Society of America.
FAU - Hajduczenia, Maria M
AU  - Hajduczenia MM
AD  - Biofilmcenter, Institute for Microbiology, Infectious Diseases and Immunology, 
      Charite-Universitatsmedizin Berlin, Berlin, Germany.
AD  - Department of Cardiology, Charite-Universitatsmedizin Berlin, Berlin, Germany.
FAU - Klefisch, Frank R
AU  - Klefisch FR
AD  - Department of Internal Medicine and Intensive Care Medicine, Paulinen Hospital 
      Berlin, Berlin, Germany.
FAU - Hopf, Alexander G M
AU  - Hopf AGM
AD  - Biofilmcenter, Institute for Microbiology, Infectious Diseases and Immunology, 
      Charite-Universitatsmedizin Berlin, Berlin, Germany.
FAU - Grubitzsch, Herko
AU  - Grubitzsch H
AD  - Department of Cardiovascular Surgery, Charite-Universitatsmedizin Berlin, Berlin, 
      Germany.
FAU - Stegemann, Miriam S
AU  - Stegemann MS
AD  - Department for Infectious Diseases and Respiratory Medicine, 
      Charite-Universitatsmedizin Berlin, Berlin, Germany.
FAU - Pfafflin, Frieder
AU  - Pfafflin F
AD  - Department for Infectious Diseases and Respiratory Medicine, 
      Charite-Universitatsmedizin Berlin, Berlin, Germany.
FAU - Puhlmann, Birgit
AU  - Puhlmann B
AD  - Department of Anesthesiology and Intensive Care Medicine, 
      Charite-Universitatsmedizin Berlin, Berlin, Germany.
FAU - Ocken, Michele
AU  - Ocken M
AD  - Department of Anesthesiology and Intensive Care Medicine, 
      Charite-Universitatsmedizin Berlin, Berlin, Germany.
FAU - Kretzler, Lucie
AU  - Kretzler L
AD  - Clinical Trial Unit, Clinical Study Center, Berlin Institute of Health (BIH), 
      Charite-Universitatsmedizin Berlin, Berlin, Germany.
FAU - von Schoning, Dinah
AU  - von Schoning D
AD  - Department of Microbiology, Labor Berlin-Charite Vivantes GmbH, Berlin, Germany.
FAU - Falk, Volkmar
AU  - Falk V
AD  - Department of Cardiovascular Surgery, Charite-Universitatsmedizin Berlin, Berlin, 
      Germany.
FAU - Moter, Annette
AU  - Moter A
AD  - Biofilmcenter, Institute for Microbiology, Infectious Diseases and Immunology, 
      Charite-Universitatsmedizin Berlin, Berlin, Germany.
AD  - MoKi Analytics GmbH, Berlin, Germany.
AD  - Moter Diagnostics, Berlin, Germany.
FAU - Kikhney, Judith
AU  - Kikhney J
AUID- ORCID: 0000-0002-4849-7947
AD  - Biofilmcenter, Institute for Microbiology, Infectious Diseases and Immunology, 
      Charite-Universitatsmedizin Berlin, Berlin, Germany.
AD  - MoKi Analytics GmbH, Berlin, Germany.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Clin Infect Dis
JT  - Clinical infectious diseases : an official publication of the Infectious Diseases 
      Society of America
JID - 9203213
RN  - 0 (RNA, Ribosomal, 16S)
SB  - IM
MH  - Humans
MH  - *Endocarditis, Bacterial/microbiology
MH  - *Heart Valve Prosthesis/adverse effects
MH  - Retrospective Studies
MH  - In Situ Hybridization, Fluorescence
MH  - RNA, Ribosomal, 16S/genetics
MH  - *Prosthesis-Related Infections/microbiology
MH  - *Endocarditis/etiology
MH  - Molecular Imaging
PMC - PMC10029985
OTO - NOTNLM
OT  - fluorescence in situ hybridization
OT  - implant infections
OT  - infectious endocarditis
OT  - molecular imaging
OT  - prosthetic valve endocarditis
COIS- Potential conflicts of interest. A. M. and J. K. are employees of and hold shares 
      in MoKi Analytics GmbH in addition to being employed by Charite, and A. M. is 
      founder and head of the private practice Moter Diagnostics. D. v. S. reports 
      support for attending meetings from Insmed Germany GmbH (participation fee NTM 
      Summit Berlin 8.10.2022). A. M. reports German Federal Ministry of Research and 
      Education (BMBF) grants 13N15824 (FIELD), 13GW0414A (PROCEED), and 13N15815 
      (TEAM) (to A. M. and J. K.; MoKi Analytics) and European Union ITN grant 814168 
      (GROWTH) (to A. M.; MoKi Analytics); honoraria for lectures by BioMerieux and 
      Chiesi; aupport for invited talks at meetings by BAMI, ECCMID, SGM, ERASMUS+, and 
      REMMDI; patents planned, issued, or pending for "Control Preparation for Fish 
      Methods in Microbiology" (PCT/EP2016/051630); a leadership or fiduciary role with 
      Konsiliarlabor Tropheryma whipplei, appointed by Robert Koch-Institute; shares 
      with MoKi Analytics GmbH, and private practice with Moter Diagnostics. J. K. 
      reports German Federal Ministry of Research and Education (BMBF) grants 13N15824 
      (FIELD), 13GW0414A (PROCEED), and 13N15815 (TEAM) (to J. K.; MoKi Analytics) and 
      European Union ITN grant 814168 (GROWTH) (to J. K.; MoKi Analytics); support for 
      attending meetings and/or travel from the German Society of Hygiene and 
      Microbiology (DGHM) (2022); patent I 07/137 (2008) Crystalline EGFR-matuzumab 
      complex and matuzumab mimetics obtained thereof; a role as Vice Speaker of the 
      Young German Society of Hygiene and Microbiology; and financial or nonfinancial 
      interests as Chief Executive Officer of MoKi Analytics GmbH, a start-up of 
      Charite, since 2018. V. F. is affiliated with the German Heart Center-Berlin, 
      Charite-University Hospital Berlin, DZHK, ETH-Zurich (Department of Health, 
      Science, and Technology and Trasl. Cardiovascular Technology). He also declares 
      institutional financial activities in relation to the following: educational 
      grants (including travel support), fees for lectures and speeches, fees for 
      professional consultation, and research and study funds with the following 
      commercial entities: Medtronic GmbH, Biotronik SE & Co, Abiomed GmbH, Abbott GmbH 
      & Co, KG, Boston Scientific, Edwards Lifesciences, Berlin Heart, Novartis Pharma 
      GmbH, JOTEC/CryoLife GmbH, LivaNova, and Zurich Heart. All other authors report 
      no potential conflicts. All authors have submitted the ICMJE Form for Disclosure 
      of Potential Conflicts of Interest. Conflicts that the editors consider relevant 
      to the content of the manuscript have been disclosed.
EDAT- 2022/11/02 06:00
MHDA- 2023/03/24 06:00
PMCR- 2022/11/01
CRDT- 2022/11/01 13:52
PHST- 2022/07/22 00:00 [received]
PHST- 2022/11/02 06:00 [pubmed]
PHST- 2023/03/24 06:00 [medline]
PHST- 2022/11/01 13:52 [entrez]
PHST- 2022/11/01 00:00 [pmc-release]
AID - 6787709 [pii]
AID - ciac860 [pii]
AID - 10.1093/cid/ciac860 [doi]
PST - ppublish
SO  - Clin Infect Dis. 2023 Mar 21;76(6):1050-1058. doi: 10.1093/cid/ciac860.